Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.1K
Overview
31.1K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

68.2K
Overview
68.2K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Antibody Response After 3-dose Booster Against Sars-cov-2 Mrna Vaccine In Kidney Transplant Recipients.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Antibody Response After 3-dose Booster Against Sars-cov-2 Mrna Vaccine In Kidney Transplant Recipients.

Related Experiment Video

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.1K

Antibody Response after 3-Dose Booster against SARS-CoV-2 mRNA Vaccine in Kidney Transplant Recipients.

Domenico Tripodi1,2, Roberto Dominici1, Davide Sacco3,4

  • 1Laboratory of Clinical Pathology and Toxicology, Hospital Pio Xi of Desio, Azienda Socio Sanitaria Territoriale della Brianza (ASST-Brianza), 20832 Desio, Italy.

Vaccines
|March 28, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Kidney transplant recipients (KTRs) show inadequate immune response to COVID-19 vaccines. Booster shots are crucial for KTRs to enhance antibody levels and protect against SARS-CoV-2 variants.

Keywords:
COVID-19NCP protein antigensS1S2

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.4K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Related Experiment Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.1K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.4K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Area of Science:

  • Immunology
  • Nephrology
  • Virology

Background:

  • Kidney transplant recipients (KTRs) face high mortality from SARS-CoV-2.
  • Existing COVID-19 vaccines offer limited protection in KTRs, with some vaccinated individuals experiencing severe disease.
  • This highlights a critical gap in vaccine-induced immunity for this immunocompromised population.

Purpose of the Study:

  • To analyze the antibody response to COVID-19 vaccines in KTRs.
  • To compare antibody levels in KTRs who contracted SARS-CoV-2 post-booster versus those who did not.
  • To investigate the association between antibody response and kidney function markers (creatinine and eGFR).

Main Methods:

  • Antibody response was analyzed in 32 KTRs using Roche and DIAPRO assays.
immunosuppressive drugs
kidney transplantation
mRNA vaccines
  • Immunotyping was employed to identify specific antibody contributions (IgG S1, IgM S2, IgA S1, IgA NCP).
  • Statistical analysis compared antibody levels pre- and post-booster and correlated them with creatinine and eGFR.

    • Main Results:

    • A significant increase in antibody response was observed post-booster compared to pre-booster.
    • IgG S1 and IgM S2 antibodies significantly contributed to the post-booster increase.
    • KTRs who contracted SARS-CoV-2 showed elevated IgA S1 and IgA NCP levels.
    • No significant association was found between antibody response and creatinine or eGFR levels.

    Conclusions:

    • KTRs require additional vaccine boosters due to their immunocompromised status and immunosuppressive therapy.
    • Enhanced antibody responses, particularly involving IgA, may be necessary for effective protection against SARS-CoV-2 and its variants in KTRs.
    • Further research into the role of specific antibody isotypes like IgA S1 and IgA NCP is warranted to optimize vaccination strategies for KTRs.